Skip to content

Comparison the effect of Piracetam versus placebo on control of Attention deficit-hyper activity disorder symptoms.

Comparison the effect of Piracetam versus placebo on control of attention deficit-hyper activity disorder symptoms in Iranian children and adolescents, a double blind randomized clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT201303036923N2
Enrollment
36
Registered
2013-08-01
Start date
2013-05-22
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention deficit-hyperactivity disorder. Disturbance of activity and attention

Interventions

Intervention 1: Intervention group will receive 70 mg/kg/day of Piracetam syrup (product of Daroo pakhsh company which contains 33.3 g/dl of drug) every morning , half an hour after taking Methylpheni
Treatment - Drugs
Placebo
Intervention group will receive 70 mg/kg/day of Piracetam syrup (product of Daroo pakhsh company which contains 33.3 g/dl of drug) every morning , half an hour after taking Methylphenidate tablet.
Control group will receive 70 mg/kg/day of placebo ( Sucrose solution in the same package and same dilution as Piracetam syrup) half an hour after taking their Methylphenidate tablet.

Sponsors

Vice chancellor for Research Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Years to 16 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria:Age 6-16; Diagnosis of ADHD for the first time Exclusion criteria : IQ<70 ; Having other chronic medical illnesses; Be under other medications; Any serious or sever complication during study; Refusal of child or parent to continue the study

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Attention, Impulsivity & Behavioral indecies. Timepoint: At the begining,3 weeks later & 6 weeks later. Method of measurement: Conner's parents questionaire.;Child's general function. Timepoint: At the begining of study , 3 weeks later , 6 weeks later. Method of measurement: CGAS questionare.

Secondary

MeasureTime frame
Drug complication. Timepoint: 3 weeks after begining of the study & 6 weeks later. Method of measurement: Rachell & klein Side effects Form.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Maryam Akbari

Tehran Institute of Psychiatry

maryam1135@yahoo.com+98 21 6655 1515

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026